Balyasny Asset Management LLC Otonomy, Inc. Transaction History

Balyasny Asset Management LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2018 Nov 14, 2018	SELL	$2.6 - $3.95 $300,942 - $457,200	-115,747 Closed	0 $0
Q2 2018 Aug 14, 2018	SELL	$3.7 - $4.75 $68,080 - $87,400	-18,400 Reduced 13.72%	115,747 $446,000
Q1 2018 May 15, 2018	BUY	$4.05 - $6.1 $356,590 - $537,086	88,047 Added 190.99%	134,147 $563,000
Q4 2017 Feb 14, 2018	SELL	$2.8 - $5.55 $1,400 - $2,775	-500 Reduced 1.07%	46,100 $256,000
Q3 2017 Nov 14, 2017	BUY	$3.2 - $20.8 $149,120 - $969,280	46,600	46,600 $151,000

Ticker OTIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,990,400
Description
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurot...

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Balyasny Asset Management LLC with notifications on news.